Researchers disclosed a first‑in‑class inhibitor targeting GAS41 (encoded by YEATS4), a chromatin‑associated protein frequently overexpressed in non‑small‑cell lung cancer (NSCLC). The new molecule acts on an epigenetic regulator implicated in NSCLC transcriptional programs and tumorigenesis, positioning GAS41 as a druggable node in chromatin biology. Preclinical data presented by the team highlighted target engagement and antitumor activity in NSCLC models, offering a new epigenetic approach distinct from histone‑modifying enzyme inhibitors. The disclosure may spur target validation efforts and partnering interest for translational development. Next steps will include optimization for selectivity and safety, and progression toward IND‑enabling studies if efficacy and tolerability signals hold.